India's New HPV Pill SHetA2: Differences from Current Vaccines
UPSC / SSC current affairs note
Why in news
India launched a free nationwide HPV vaccination campaign on February 28, 2026. Amid this, a new HPV pill called SHetA2 has been developed, raising questions about how it differs from existing vaccines.
Background
Human papillomavirus (HPV) is a common sexually transmitted infection that can cause cervical cancer. Current HPV vaccines are injectable and prevent infection. SHetA2 is a novel oral pill being developed as an alternative.
Key facts
SHetA2 is a new oral pill for HPV, unlike current injectable vaccines.
It is still under development and not yet approved for public use.
Current HPV vaccines (e.g., Gardasil, Cervarix) are given as injections.
The pill may offer easier administration and better compliance.
India launched a free nationwide HPV vaccination campaign on February 28, 2026.
HPV is linked to cervical cancer, a major health concern in India.
Prelims pointers
- SHetA2: oral HPV pill under development
- HPV: Human papillomavirus
- Cervical cancer: caused by HPV
- Current vaccines: Gardasil, Cervarix (injectable)
- National HPV vaccination campaign launched Feb 28, 2026
Mains angles
- GS2: Government policies and interventions for health sector
- GS3: Science and technology in healthcare; vaccine development
- GS2: Issues related to women's health and cervical cancer prevention